#BEGIN_DRUGCARD DB01125

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Accumulation does not occur with repeated dosing.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Miradon
Unidone

# CAS_Registry_Number:
117-37-3

# ChEBI_ID:
133809

# Chemical_Formula:
C16H12O3

# Chemical_IUPAC_Name:
2-(4-methoxyphenyl)-2,3-dihydro-1H-indene-1,3-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Anisindione is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K-mediated gamma-carboxylation of precursor proteins.

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Anticoagulants

# Drug_Interactions:
Acetaminophen	Acetaminophen increases the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if acetaminophen is initiated, discontinued or dose changed.
Acetylsalicylic acid	Acetylsalicylic acid increases effect of the anticoagulant, anisindione.
Allopurinol	Allopurinol may increase the anticoagulant effect of anisindione.
Aminoglutethimide	Aminoglutethimide may decrease the anticoagulant effect of anisindione.
Amiodarone	Amiodarone may increase the anticoagulant effect of anisindione.
Amprenavir	Amprenavir may increase the anticoagulant effect of anisindione by increasing its serum concentration.
Aprepitant	Aprepitant may decrease the anticoagulant effect of anisindione by decreasing its serum concentration.
Atazanavir	The protease inhibitor, atazanavir, may increase the anticoagulant effect of anisindione.
Azathioprine	Azathioprine may decrease the anticoagulant effect of anisindione.
Azithromycin	Azithromycin may increase the anticoagulant effect of anisindione by increasing its serum concentration.
Betamethasone	The corticosteroid, betamethasone, alters the anticoagulant effect of anisindione.
Bosentan	Bosentan may decrease the anticoagulant effect of anisindione by increasing its metabolism.
Capecitabine	Capecitabine may increase the anticoagulant effect of anisindione by increasing its serum concentration.
Carbamazepine	Carbamazepine may decrease the anticoagulant effect of anisindione by decreasing its serum concentration.
Cefotetan	The cephalosporin, cefotetan, may increase the anticoagulant effect of anisindione.
Cefoxitin	The cephalosporin, cefoxitin, may increase the anticoagulant effect of anisindione.
Ceftriaxone	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of anisindione.
Celecoxib	Celecoxib may increase the anticoagulant effect of anisindione.
Cholestyramine	The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of anisindione by decreasing its absorption.
Cimetidine	Cimetidine may increase the anticoagulant effect of anisindione.
Ciprofloxacin	The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of anisindione.
Cisapride	Cisapride may increase the anticoagulant effect of anisindione.
Citalopram	The SSRI, citalopram, increases the effect of anticoagulant, anisindione.
Clarithromycin	The macrolide, clarithromycin, may increase the anticoagulant effect of anisindione.
Clofibrate	The fibrate increases the anticoagulant effect
Colestipol	The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of anisindione by decreasing its absorption.
Cyclophosphamide	The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of anisindione.
Danazol	The androgen, danazol, may increase the anticoagulant effect of anisindione.
Demeclocycline	The tetracycline, demeclocycline, may increase the anticoagulant effect of anisindione.
Dexamethasone	The corticosteroid, dexamethasone, alters the anticoagulant effect of anisindione.
Dextrothyroxine	The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of anisindione.
Diclofenac	The NSAID, diclofenac, may increase the anticoagulant effect of anisindione.
Dicloxacillin	Dicloxacillin may decrease the anticoagulant effect of anisindione.
Diflunisal	The NSAID, diflunisal, may increase the anticoagulant effect of anisindione.
Disulfiram	Disulfiram may increase the anticoagulant effect of anisindione.
Doxycycline	The tetracycline, doxycycline, may increase the anticoagulant effect of anisindione.
Erythromycin	The macrolide, erythromycin, may increase the anticoagulant effect of anisindione.
Ethchlorvynol	Ethchlorvynol may decrease the anticoagulant effect of anisindione.
Ethinyl Estradiol	Increased thrombotic risk due to estrogen
Etodolac	The NSAID, etodolac, may increase the anticoagulant effect of anisindione.
Etoricoxib	Etoricoxib may increase the anticoagulant effect of anisindione.
Fenofibrate	Fenofibrate may increase the anticoagulant effect of anisindione.
Fenoprofen	The NSAID, fenoprofen, may increase the anticoagulant effect of anisindione.
Fluconazole	Fluconazole may increase the serum concentration of anisindione by decreasing its metabolism.
Fludrocortisone	The corticosteroid, fludrocortisone, alters the anticoagulant effect of anisindione.
Fluorouracil	The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of anisindione.
Fluoxetine	The SSRI, fluoxetine, increases the effect of anticoagulant, anisindione.
Fluoxymesterone	The androgen, fluoxymesterone, may increase the anticoagulant effect of anisindione.
Flurbiprofen	The NSAID, flurbiprofen, may increase the anticoagulant effect anisindione.
Fluvastatin	Fluvastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if fluvastatin if initiated, discontinued or dose changed.
Fluvoxamine	Fluvoxamine may increase the anticoagulant effect of anisindione by increasing its serum concentration.
Fosamprenavir	The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of anisindione.
Fosphenytoin	Increased hydantoin levels and risk of bleeding
Gefitinib	Gefitinib may increase the anticoagulant effect of anisindione.
Gemcitabine	Gemcitabine may increase the anticoagulant effect of anisindione.
Gemfibrozil	Gemfibrozil may increase the anticoagulant effect of anisindione.
Glutethimide	Glutethimide may decrease the anticoagulant effect of anisindione.
Griseofulvin	Griseofulvin may decrease the anticoagulant effect of anisindione.
Hydrocortisone	The corticosteroid, hydrocortisone, alters the anticoagulant effect of anisindione.
Ibuprofen	The NSAID, ibuprofen, may increase the anticoagulant effect of anisindione.
Imatinib	Imatinib may increase the anticoagulant effect of anisindione.
Indinavir	The protease inhibitor, indinavir, may increase the anticoagulant effect of anisindione.
Indomethacin	The NSAID, indomethacin, may increase the anticoagulant effect of anisindione.
Isoniazid	Isoniazid may increase the anticoagulant effect of anisindione.
Itraconazole	Itraconazole may increase the anticoagulant effect of anisindione.
Ketoconazole	Ketoconazole may increase the anticoagulant effect of anisindione.
Ketoprofen	The NSAID, ketoprofen, may increase the anticoagulant effect of anisindione.
Ketorolac	The NSAID, ketorolac, may increase the anticoagulant effect of anisindione.
Leflunomide	Leflunomide may increase the anticoagulant effect of anisindione.
Levamisole	Levamisole may increase the anticoagulant effect of anisindione.
Levofloxacin	The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of anisindione.
Levothyroxine	The thyroid hormone, levothyroxine, increase the anticoagulant effect of anisindione.
Lovastatin	Lovastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if lovastatin if initiated, discontinued or dose changed.
Lumiracoxib	Lumiracoxib may increase the anticoagulant effect of anisindione.
Medroxyprogesterone	Medroxyprogesterone may increase the anticoagulant effect of anisindione.
Mefenamic acid	The NSAID, mefanamic acid, may increase the anticoagulant effect of anisindione.
Mefloquine	Mefloquine may increase the anticoagulant effect of anisindione.
Meloxicam	Meloxicam may increase the anticoagulant effect of anisindione.
Mercaptopurine	Mercaptopurine may decrease the anticoagulant effect of anisindione.
Methimazole	The antithyroid agent, methimazole, may decrease the anticoagulant effect of anisindione.
Metronidazole	Metronidazole may increase the anticoagulant effect of anisindione.
Miconazole	Miconazole may increase the serum concentration of anisindione by decreasing its metabolism.
Minocycline	The tetracycline, minocycline, may increase the anticoagulant effect of anisindione.
Mitotane	Mitotane may decrease the anticoagulant effect of anisindione.
Moxifloxacin	The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of anisindione.
Nabumetone	The NSAID, nabumetone, may increase the anticoagulant effect anisindione.
Nalidixic Acid	The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of anisindione.
Naproxen	The NSAID, naproxen, may increase the anticoagulant effect of anisindione.
Nelfinavir	The protease inhibitor, nelfinavir, may increase the anticoagulant effect of anisindione.
Nevirapine	Nevirapine may decrease the anticoagulant effect of anisindione.
Norfloxacin	The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of anisindione.
Ofloxacin	The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of anisindione.
Orlistat	Orlistat may increase the anticoagulant effect of anisindione.
Oxaprozin	The NSAID, oxaprozin, may increase the anticoagulant effect of anisinodione.
Oxyphenbutazone	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of anisindione.
Paroxetine	The SSRI, paroxetine, increases the effect of the anticoagulant, anisindione.
Pentoxifylline	Pentoxifylline may increase the anticoagulant effect of anisindione.
Phenobarbital	The barbiturate, phenobarbital, decreases the anticoagulant effect of anisindione.
Phenylbutazone	The NSAID, phenylbutazone, may increase the anticoagulant effect of anisindione.
Phenytoin	Increased hydantoin levels and risk of bleeding
Piroxicam	The NSAID, piroxicam, may increase the anticoagulant effect of anisindione.
Prednisolone	The corticosteroid, prednisolone, alters the anticoagulant effect of anisindione.
Prednisone	The corticosteroid, prednisone, alters the anticoagulant effect of anisindione.
Primidone	The barbiturate, primidone, decreases the anticoagulant effect of anisindione.
Propafenone	Propafenone may increase the anticoagulant effect of anisindione.
Propoxyphene	Propoxyphene may increase the anticoagulant effect of anisindione.
Propylthiouracil	The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of anisindione.
Quinidine	Quinidine may increase the anticoagulant effect of anisindione.
Quinine	Quinine may increase the anticoagulant effect of anisindione.
Ranitidine	Ranitidine may increase the anticoagulant effect of anisindione. (Conflicting evidence)
Rifabutin	Rifabutin, may decrease the anticoagulant effect of anisindione.
Rifampin	Rifampin may decrease the anticoagulant effect of anisindione.
Telithromycin	Telithromycin may increase the anticoagulant effect of anisindione.
Tenoxicam	The NSAID, tenoxicam, may increase the anticoagulant effect of anisindione.
Testosterone	The androgen may increase the anticoagulant effect of anisindione.
Tetracycline	Tetracycline may increase the anticoagulant effect of anisindione.
Tigecycline	Tigecycline may increase the anticoagulant effect of anisindione.
Triamcinolone	The corticosteroid, triamcinolone, alters the anticoagulant effect of anisindione.

# Drug_Reference:
13652026	CONNELL WF, MAYER GA: Evaluation of anticoagulant therapy with anisindione (miradon). Can Med Assoc J. 1959 May 15;80(10):785-90.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.88

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
79.8 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Anisindione

# HET_ID:
Not Available

# Half_Life:
Not Known

# InChI_Identifier:
InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3

# InChI_Key:
InChIKey=XRCFXMGQEVUZFC-UHFFFAOYSA-N

# Indication:
For the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1125

# Mechanism_Of_Action:
Like phenindione, to which it is related chemically, anisindione exercises its therapeutic action by reducing the prothrombin activity of the blood. Anisindione prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K&ndash;mediated gamma-carboxylation of precursor proteins. Anisindione has no direct thrombolytic effect and does not reverse ischemic tissue damage, although it may limit extension of existing thrombi and prevent secondary thromboembolic complications.

# Melting_Point:
156.5 Â°C

# Molecular_Weight_Avg:
252.2647

# Molecular_Weight_Mono:
252.07864425

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/mir1623.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164746467

# Pharmacology:
Anisindione is a synthetic anticoagulant and an indanedione derivative. It is prescribed only if you cannot take coumarin-type anticoagulants such as coumadin as anisindione is a powerful drug with serious potential side effects. Anticoagulants decrease the clotting ability of the blood and therefore help to prevent harmful clots from forming in the blood vessels. These medicines are sometimes called blood thinners, although they do not actually thin the blood. They also will not dissolve clots that already have formed, but they may prevent the clots from becoming larger and causing more serious problems.

# Predicted_LogP_Hydrophobicity:
2.99

# Predicted_LogS:
-4.3

# Predicted_Water_Solubility:
1.28e-02 g/l

# Primary_Accession_No:
DB01125

# Protein_Binding:
Not Known

# PubChem_Compound_ID:
2197

# PubChem_Substance_ID:
46504660

# RxList_Link:
http://www.rxlist.com/cgi/generic/miradon.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00799

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Anisin indandione

# Synthesis_Reference:
Not Available

# Toxicity:
An overdose is likely to cause abnormal bleeding, for which the symptoms include: bleeding from gums or nose, blood in urine or stools, excessive bleeding from minor cuts, patches of discoloration or bruises on the skin.

# Update_Date:
2013-02-08 16:19:55 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Anisindione

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
GGCX

# Drug_Target_1_GenBank_ID_Gene:
M81592

# Drug_Target_1_GenBank_ID_Protein:
184028

# Drug_Target_1_GeneCard_ID:
GGCX

# Drug_Target_1_Gene_Name:
GGCX

# Drug_Target_1_Gene_Sequence:
>2277 bp
ATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGAC
AAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTT
GAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGAC
CCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCC
CAGGAGCGGGGGCTCAGCTCTCTGGACCGGAAATACCTTGATGGGCTGGATGTGTGCCGC
TTCCCCTTGCTGGATGCCCTACGCCCACTGCCACTTGACTGGATGTATCTTGTCTACACC
ATCATGTTTCTGGGGGCACTGGGCATGATGCTGGGCCTGTGCTACCGGATAAGCTGTGTG
TTATTCCTGCTGCCATACTGGTATGTGTTTCTCCTGGACAAGACATCATGGAACAACCAC
TCCTATCTGTATGGGTTGTTGGCCTTTCAGCTAACATTCATGGATGCAAACCACTACTGG
TCTGTGGACGGTCTGCTGAATGCCCATAGGAGGAATGCCCACGTGCCCCTTTGGAACTAT
GCAGTGCTCCGTGGCCAGATCTTCATTGTGTACTTCATTGCGGGTGTGAAAAAGCTGGAT
GCAGACTGGGTTGAAGGCTATTCCATGGAATATTTGTCCCGGCACTGGCTCTTCAGTCCC
TTCAAACTGCTGTTGTCTGAGGAGCTGACTAGCCTGCTGGTCGTGCACTGGGGTGGGCTG
CTGCTTGACCTCTCAGCTGGTTTCCTGCTCTTTTTTGATGTCTCAAGATCCATTGGCCTG
TTCTTTGTGTCCTACTTCCACTGCATGAATTCCCAGCTTTTCAGCATTGGTATGTTCTCC
TACGTCATGCTGGCCAGCAGCCCTCTCTTCTGCTCCCCTGAGTGGCCTCGGAAGCTGGTG
TCCTACTGCCCCCAAAGGTTGCAACAACTGTTGCCCCTCAAGGCAGCCCCTCAGCCCAGT
GTTTCCTGTGTGTATAAGAGGAGCCGGGGCAAAAGTGGCCAGAAGCCAGGGCTGCGCCAT
CAGCTGGGAGCTGCCTTCACCCTGCTCTACCTCCTGGAGCAGCTATTCCTGCCCTATTCT
CATTTTCTCACCCAGGGCTATAACAACTGGACAAATGGGCTGTATGGCTATTCCTGGGAC
ATGATGGTGCACTCCCGTTCCCACCAGCACGTGAAGATCACCTACCGTGATGGCCGCACT
GGCGAACTGGGCTACCTTAACCCTGGGGTATTTACACAGAGTCGGCGATGGAAGGATCAT
GCAGACATGCTGAAGCAATATGCCACTTGCCTGAGCCGCCTGCTTCCCAAGTATAATGTC
ACTGAGCCCCAGATCTACTTTGATATTTGGGTCTCCATCAATGACCGCTTCCAGCAGAGG
ATTTTTGACCCTCGTGTGGACATCGTGCAGGCCGCTTGGTCACCCTTTCAGCGCACATCC
TGGGTGCAACCACTCTTGATGGACCTGTCTCCCTGGAGGGCCAAGTTACAGGAAATCAAG
AGCAGCCTAGACAACCACACTGAGGTGGTCTTCATTGCAGATTTCCCTGGACTGCACTTG
GAGAATTTTGTGAGTGAAGACCTGGGCAACACTAGCATCCAGCTGCTGCAGGGGGAAGTG
ACTGTGGAGCTTGTGGCAGAACAGAAGAACCAGACTCTTCGAGAGGGAGAAAAAATGCAG
TTGCCTGCTGGTGAGTACCATAAGGTGTATACGACATCACCTAGCCCTTCTTGCTACATG
TACGTCTATGTCAACACTACAGAGCTTGCACTGGAGCAAGACCTGGCATATCTGCAAGAA
TTAAAGGAAAAGGTGGAGAATGGAAGTGAAACAGGGCCTCTACCCCCAGAGCTGCAGCCT
CTGTTGGAAGGGGAAGTAAAAGGGGGCCCTGAGCCAACACCTCTGGTTCAGACCTTTCTT
AGACGCCAACAAAGGCTCCAGGAGATTGAACGCCGGCGAAATACTCCTTTCCATGAGCGA
TTCTTCCGCTTCTTGTTGCGAAAGCTCTATGTCTTTCGCCGCAGCTTCCTGATGACTTGT
ATCTCACTTCGAAATCTGATATTAGGCCGTCCTTCCCTGGAGCAGCTGGCCCAGGAGGTG
ACTTATGCAAACTTGAGACCCTTTGAGGCAGTTGGAGAACTGAATCCCTCAAACACGGAT
TCTTCACATTCTAATCCTCCTGAGTCAAATCCTGATCCTGTCCACTCAGAGTTCTGA

# Drug_Target_1_General_Function:
Involved in gamma-glutamyl carboxylase activity

# Drug_Target_1_General_References:
11071668	Spronk HM, Farah RA, Buchanan GR, Vermeer C, Soute BA: Novel mutation in the gamma-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors. Blood. 2000 Nov 15;96(10):3650-2.
1749935	Wu SM, Cheung WF, Frazier D, Stafford DW: Cloning and expression of the cDNA for human gamma-glutamyl carboxylase. Science. 1991 Dec 13;254(5038):1634-6.
9166845	Wu SM, Stafford DW, Frazier LD, Fu YY, High KA, Chu K, Sanchez-Vega B, Solera J: Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase. Blood. 1997 Jun 1;89(11):4058-62.
9845520	Brenner B, Sanchez-Vega B, Wu SM, Lanir N, Stafford DW, Solera J: A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. Blood. 1998 Dec 15;92(12):4554-9.

# Drug_Target_1_HGNC_ID:
HGNC:4247

# Drug_Target_1_HPRD_ID:
00665

# Drug_Target_1_ID:
448

# Drug_Target_1_Locus:
2p12

# Drug_Target_1_Molecular_Weight:
87562

# Drug_Target_1_Name:
Vitamin K-dependent gamma-carboxylase

# Drug_Target_1_Number_of_Residues:
758

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Acenocoumarol Pathway	SMP00269
Dicumarol Pathway	SMP00270
Phenprocoumon Pathway	SMP00271
Warfarin Pathway	SMP00268

# Drug_Target_1_Pfam_Domain_Function:
PF05090	VKG_Carbox

# Drug_Target_1_Protein_Sequence:
>Vitamin K-dependent gamma-carboxylase
MAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTD
PASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYT
IMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYW
SVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSP
FKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFS
YVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRH
QLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRT
GELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQR
IFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHL
ENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYM
YVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFL
RRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEV
TYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium binding gamma-carboxyglutamate (Gla) residues with the concomitant convertion of the reduced hydroquinone form of vitamin K to vitamin K epoxide

# Drug_Target_1_SwissProt_ID:
P38435

# Drug_Target_1_SwissProt_Name:
VKGC_HUMAN

# Drug_Target_1_Synonyms:
EC 6.4.-.-
Gamma-glutamyl carboxylase
Vitamin K gamma glutamyl carboxylase

# Drug_Target_1_Theoretical_pI:
8.10

# Drug_Target_1_Transmembrane_Regions:
61-81
114-134
137-157
293-313
362-382

#END_DRUGCARD DB01125
